Last week, Compass Pathways (CMPS) commenced trading on the Nasdaq and became the first psychedelic drug company to go public on a major U.S. stock exchange. When Compass filed to go public, the deal generated substantially more interest from investors than expected. As a result, the psychedelic therapy company upsized…
Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ"). As part of this up-listing strategy in the United States, MindMed has submitted an application to list its subordinate…
After Champignon Brands was issued a cease trade order from the SEC, the entire psychedelic therapy sector came under pressure and this is a trend that we have been closely following. Although we believe that investors need to conduct significant due diligence and be selective when it comes to the…
2020 has been a challenging year for the global economy and the COVID pandemic has made an impact on the mental health market. We believe that the pandemic has served as a catalyst for the psychedelic therapy market as healthcare providers and researchers seek new ways to treat debilitating mental…
Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), is pleased to announce that it has closed its previously announced short form prospectus offering, on a best efforts basis, including the exercise of the agent's option in its entirety in the form of units of the Company (each, a "Unit"). A…
Rritual, the premium brand in the emerging functional mushroom market, announced today that it will launch its suite of premium mushroom and adaptogen enhanced elixirs this fall. Made from a proprietary blend of organic mushrooms and time-tested adaptogenic herbs, Rritual's easy-to-mix elixirs are formulated to blend into your daily wellness…
AWAKN Life Sciences Inc ("AWAKN"), the European psychedelic assisted psychotherapy company, today announces the launch of its Commercial Clinical Research Division. AWAKN's purpose is broadening access to psychedelic assisted psychotherapy and integrating these services into mainstream mental healthcare in Europe across three business divisions of Clinical Research, Therapeutic Clinics, and…
2020 has been a banner year for the psychedelic sector and we believe that the industry is in the early stages of a major growth cycle. Last week, Compass Pathways announced a major milestone and filed to go public on the Nasdaq Global Market under the symbol CMPS. The leading…
Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial results for the three and six months ended June 30, 2020. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and…
Although the functional mushroom market has been getting a lot of attention, we are most excited about the progress that has been made on the biotech side of the psychedelic industry. There are a few companies in advanced stages of U.S. Food and Drug Administration (FDA) clinical trials and the…
